The WHO ranks Tuberculosis as “the second leading cause of death from a single infectious agent”. It is estimated that in 2013, there were 9 million new TB cases and 1.1 million deaths resulting from TB worldwide. To make the situation worse, the problem of multidrug resistance is increasingly severe. According to the WHO, in 2013, there were approximately 480,000 new MDR-TB cases and 210,000 deaths resulting from MDR-TB around the world. The WHO points out that “laboratory confirmation of TB and drug resistance” is critical to ensuring correct diagnosis and correct treatment for individuals with TB signs and symptoms. CapitalBio Tuberculosis and Non-Tuberculous Mycobacteria Real-Time PCR Detection Kit and CapitalBio M. tuberculosis Drug Resistance Detection Array Kit constitute useful tools for “laboratory confirmation of TB and drug resistance”. Together with CapitalBio Mycobacterial Species Identification Array Kit and Aminoglycoside-Induced Deafness Gene Mutations Detection Kit, they help to ensure correct diagnosis and correct treatment for individuals with TB signs and symptoms.
● CapitalBio Tuberculosis and Non-Tuberculous Mycobacteria Real-Time PCR Detection Kit is designed for a rapid and accurate screening of MTB/NTM infection. It employs duplex real-time fluorescence PCR technology and detects both MTB infection and NTM infection with only one test. Its detection limit for MTB is 10 CFU/PCR and its detection limit for NTM is 100 CFU/PCR. The testing process takes only 3 hours. 1017 clinical tests demonstrate that its specificity is 99%. It is compatible with a variety of fluorescence PCR systems.